Ganirelix (acetate)

Ganirelix (acetate)

• CAS Number: 129311-55-3
• UNSPSC Description: Ganirelix acetate (Ganirest) is an injectable competitive gonadotropin-releasing hormone (GnRH) antagonist. Ganirelix acetate directly competes against the endogenous molecule for receptor binding, and causes a rapid reduction in estradiol levels. Ganirelix acetate can be used for researching ovarian hyperstimulation syndrome (OHSS)[1].
• Target Antigen: GnRH Receptor
• Type: Reference compound
• Related Pathways: GPCR/G Protein
• Applications: Metabolism-protein/nucleotide metabolism
• Field of Research: Metabolic Disease
• Assay Protocol: https://www.medchemexpress.com/ganirelix-acetate.html
• Purity: 98.03
• Solubility: H2O : 50 mg/mL (ultrasonic)
• Smiles: OC(C=C1)=CC=C1C[C@H](NC([C@H](CO)NC([C@@H](CC2=CN=CC=C2)NC([C@H](NC([C@H](NC(C)=O)CC3=CC4=CC=CC=C4C=C3)=O)CC5=CC=C(Cl)C=C5)=O)=O)=O)C(N[C@H](CCCC/N=C(NCC)/NCC)C(N[C@@H](CC(C)C)C(N[C@@H](CCCC/N=C(NCC)/NCC)C(N6[C@@H](CCC6)C(N[C@H](C)C(N)=O)=O)=O)=O)=O)=O.CC(O)=O.CC(O)=O
• Molecular Weight: 1690.42
• References & Citations: [1]Gustofson RL, et al. Ganirelix acetate causes a rapid reduction in estradiol levels without adversely affecting oocyte maturation in women pretreated with leuprolide acetate who are at risk of ovarian hyperstimulation syndrome. Hum Reprod. 2006 Nov;21(11):2830-7.
• Shipping Conditions: Blue Ice
• Storage Conditions: -20°C (Powder, protect from light, stored under nitrogen)
• Clinical Information: Launched